by MATTHEW PERRONE This 2018 photo provided by Amylyx shows the company’s co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. on Sept. 2, 2022. A closely watched experimental drug for Lou Gehrig’s disease is getting an unusual second look from U.S. regulators on Wednesday, Sept. 7, 2022, amid intense pressure to approve the...
